Motus GI yesterday set the range for its pending initial public offering, which at the midpoint would fetch nearly $26 million.
Last month the Israeli company, which makes the Pure-Vu intra-colonoscopy cleaning system, registered the IPO at roughly $28.8 million. Motus GI won FDA clearance for the device in September 2016.
Yesterday Motus said it plans to float 4.25 million shares at $5 to $7 apiece, for a range of about $21.3 million to nearly $29.8 million.
The company said it plans to list on the NASDAQ exchange under the symbol “MOTS,” noting that Piper Jaffray and Oppenheimer are acting as joint bookrunners for the offering.
Eleven months ago Motus closed a $30 million private placement to back the commercial launch of its Pure-Vu colonoscopy system.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.